Skip to main content
Fagron N.V. logo

Fagron N.V. — Investor Relations & Filings

Ticker · FAGR ISIN · BE0003874915 LEI · 549300TRKRUFK2RRG779 BR Manufacturing
Open in API
Filings indexed 1,987 across all filing types
Latest filing 2026-02-12 Earnings Release
Country BE Belgium
Listing BR FAGR

About Fagron N.V.

https://fagron.com/

Fagron N.V. is a global company active in pharmaceutical compounding, focusing on the delivery of personalized medicine. The company optimizes and innovates compounding to widen the therapeutic options for prescribers worldwide. Fagron develops, markets, and distributes pharmaceutical raw materials, equipment, and specially formulated vehicles and bases, such as the Pentravan® transdermal base and the SyrSpend® range of oral suspending vehicles. Its primary customers are hospitals, pharmacies, and clinics. The company also operates in the field of genomics to further support personalized healthcare solutions.

Recent filings

Filing Released Lang Actions
Fagron continues its outstanding performance in FY 2025 with 9.2% topline growth and 10.9% increase in REBITDA.pdf
Earnings Release Classification · 98% confidence The document is a comprehensive financial results announcement for the fiscal year 2025, titled 'Fagron continues its outstanding performance in FY 2025'. It contains detailed financial tables (Revenue, REBITDA, EPS), regional business reviews, M&A activity summaries, and forward-looking guidance. While it contains highlights, the length and depth of the financial data and operational review classify it as an Earnings Release (ER) rather than a simple report publication announcement or a full 10-K annual report. FY 2025
2026-02-12 English
Fagron behoudt uitstekende prestaties in boekjaar 2025 met 9,2% omzetgroei en een stijging van de REBITDA met 10,9% .pdf
Earnings Release Classification · 98% confidence The document is a comprehensive financial results announcement for the fiscal year 2025, detailing revenue growth, REBITDA, cash flow, M&A activity, and future outlook. It provides detailed financial tables and management commentary. While it contains highlights, the length and depth of the financial data and operational review classify it as an Earnings Release (ER) rather than a simple report publication announcement or a full 10-K annual report. FY 2025
2026-02-12 Dutch
Fagron obtains regulatory clearance for the acquisition of Vepakum in Brazil and completes the acquisition of Magilab in Hungary
M&A Activity Classification · 100% confidence The document is a press release announcing the acquisition of Vepakum and the completion of the acquisition of Magilab by Fagron. It details the strategic rationale for these acquisitions and provides a financial calendar. Since the document focuses on merger and acquisition activity, it falls under the M&A Activity category.
2026-02-05 Dutch
Fagron obtains regulatory clearance for the acquisition of Vepakum in Brazil and completes the acquisition of Magilab in Hungary
M&A Activity Classification · 100% confidence The document is a press release announcing the acquisition of two companies (Vepakum and Magilab) by Fagron. It details the strategic rationale for these acquisitions and provides a financial calendar. Since the primary purpose of the document is to announce M&A activity, it falls under the M&A Activity category.
2026-02-05 English
Fagron obtains regulatory clearance for the acquisition of Vepakum in Brazil and completes the acquisition of Magilab in Hungary.pdf
M&A Activity Classification · 100% confidence The document is a press release announcing the acquisition of two companies (Vepakum and Magilab) by Fagron. It details the strategic rationale for these acquisitions and provides a financial calendar. Since the primary purpose of the document is to announce M&A activity, it falls under the M&A Activity category.
2026-02-05 English
Fagron verkrijgt goedkeuring van lokale autoriteiten voor de overname van Vepakum in Brazilië en rondt de overname van Magilab in Hongarije af.pdf
M&A Activity Classification · 100% confidence The document is a press release announcing the acquisition of Vepakum and the completion of the acquisition of Magilab by Fagron. It details the strategic rationale for these acquisitions and provides a financial calendar. Since the document focuses on merger and acquisition activity, it falls under the M&A Activity category.
2026-02-05 Dutch

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.